| Literature DB >> 28502040 |
Xuewei Chen1,2,3, Liping Liu2,3, Zhihua Guo1,3, Wenhua Liang1,3, Jiaxi He1,3, Liyan Huang2,3, Qiuhua Deng2,3, Hailing Tang2,3, Hui Pan2,3, Minzhang Guo1,2,3, Yang Liu1,3, Qihua He1,3, Jianxing He4,5,6.
Abstract
Previous studies of irinotecan pharmacogenetics have shown that the UGT1A1*28 polymorphism has an effect on irinotecan (IRI)-induced toxicities in Caucasians. Yet compared with the UGT1A1*6 mutation, the UGT1A1*28 occurs at a much lower frequency in the Asians. Whether UGT1A1*6 and UGT1A1*28 are associated with IRI-induced neutropenia, diarrhea and IRI-based chemotherapy tumor response (TR) in Asians with lung cancer remains controversial. In this meta-analysis, we found a higher risk of neutropenia and diarrhea with IRI-based chemotherapy in Asians with lung cancer carrying the UGT1A1*6 polymorphism. However, UGT1A1*28 showed a weak correlation with diarrhea, but no significant correlation with neutropenia. Neither UGT1A1*6 nor UGT1A1*28 is associated with IRI-based chemotherapy TR. These data suggest that the UGT1A1*28 polymorphism may not be a suitable biomarker to predict IRI-induced toxicities and chemotherapy TR in Asians, while UGT1A*6 polymorphism is associated with a higher risk of IRI-induced neutropenia and diarrhea, but not IRI-based chemotherapy TR.Entities:
Keywords: Asians; Irinotecan; Lung cancer; Toxicity; Tumor response; UGT1A1 polymorphism
Mesh：
Substances：
Year: 2017 PMID： 28502040 DOI： 10.1007/s00280-017-3306-9
Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333